Atypical variants in COL1A1 and COL3A1 associated with classical and vascular Ehlers-Danlos syndrome overlap phenotypes: expanding the clinical phenotype based on additional case reports.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
May 2022
Historique:
received: 29 11 2021
accepted: 20 04 2022
entrez: 19 5 2022
pubmed: 20 5 2022
medline: 24 5 2022
Statut: ppublish

Résumé

The vast majority of reported (likely) pathogenic missense variants in the genes coding for the fibrillar collagens leads to the substitution of one of the obligatory glycine residues in the Gly-Xaa-Yaa repeat sequence of the triple helical domain. Their phenotypic consequences and deleterious effects have been well-documented. However, with increasing access to molecular diagnostic testing based on next-generation sequencing techniques, such as sequencing of multi-gene panels and whole-exome sequencing, non-glycine substitutions are more frequently identified in individuals suspected to have a heritable collagen disorder, but their pathogenic effect is often difficult to predict.Some specific non-glycine substitutions in the proα1(I)- (p.(Arg312Cys)) and proα1(III)- (glutamic acid to lysine at different positions) collagen chain have been identified in a number of individuals presenting a phenotype showing features of both classical and vascular Ehlers-Danlos syndrome. The number of reported individuals with these defects is currently very low, and several of these non-glycine substitutions had initially been categorised as variants of unknown significance (VUS), complicating early diagnosis, accurate counselling, management guidelines, and correct classification. This collaborative study reports on the phenotype of 22 and 7 individuals harbouring these rare variants in COL1A1 and COL3A1, respectively, expanding our knowledge on clinical presentation, phenotypic variability, and natural history, and informing on the risk for potentially life-threatening events, such as vascular, gastro-intestinal, and pregnancy-related complications.

Identifiants

pubmed: 35587586
pii: 18165
doi: 10.55563/clinexprheumatol/kzkq6y
doi:

Substances chimiques

COL1A1 protein, human 0
COL3A1 protein, human 0
Collagen Type I, alpha 1 Chain 0
Collagen Type III 0
Collagen 9007-34-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-62

Auteurs

Marlies Colman (M)

Centre for Medical Genetics, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Belgium.

Marco Castori (M)

Division of Medical Genetics, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.

Lucia Micale (L)

Division of Medical Genetics, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.

Marco Ritelli (M)

Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Italy.

Marina Colombi (M)

Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Italy.

Neeti Ghali (N)

Ehlers-Danlos Syndrome National Diagnostic Service London, North West Thames Regional Genetics Service, London North West Healthcare University NHS Trust, Harrow, Middlesex, UK.

Fleur Van Dijk (F)

National Ehlers Danlos Syndrome Diagnostic Service, Northwick Park and St. Mark's Hospitals, Harrow, UK.

Luisa Marsili (L)

Clinique de Génétique, CHU Lille, France and Utrecht University, University Medical Center Utrecht, Department of Genetics, Utrecht, The Netherlands.

Adrienne Weeks (A)

Neurosurgery, Dalhousie University, Halifax, Nova Scotia, Canada.

Anthony Vandersteen (A)

Maritime Medical Genetics Service, IWK Health Centre, Halifax, Nova Scotia, Canada.

Andrea Rideout (A)

Maritime Medical Genetics Service, IWK Health Centre, Halifax, Nova Scotia, Canada.

Anne Legrand (A)

Département de Génétique, Centre National de Référence pour les Maladies Vasculaires Rares, Centre de Référence Européen VASCERN MSA, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Michael Frank (M)

Département de Génétique, Centre National de Référence pour les Maladies Vasculaires Rares, Centre de Référence Européen VASCERN MSA, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Tristan Mirault (T)

Département de Génétique, Centre National de Référence pour les Maladies Vasculaires Rares, Centre de Référence Européen VASCERN MSA, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Alessandro Ferraris (A)

Medical Genetics Unit, Experimental Medicine Department, Sapienza University, San Camillo-Forlanini Hospital, Rome, Italy.

Niccolò Di Giosaffatte (N)

Medical Genetics Unit, Experimental Medicine Department, Sapienza University, San Camillo-Forlanini Hospital, Rome, Italy.

Paola Grammatico (P)

Medical Genetics Unit, Experimental Medicine Department, Sapienza University, San Camillo-Forlanini Hospital, Rome, Italy.

Juergen Grunert (J)

Deutsche Ehlers-Danlos Initiative e.V., Fürth, Germany.

Charissa Frank (C)

Bindweefsel.be, Koersel, Belgium.

Sofie Symoens (S)

Centre for Medical Genetics, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Belgium.

Delfien Syx (D)

Centre for Medical Genetics, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Belgium.

Fransiska Malfait (F)

Centre for Medical Genetics, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Belgium. fransiska.malfait@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH